Author

Simon Nitschky Schmidt

Observed names: S. Nitschky Schmidt, S. Schmidt, Schmidt, Simon, Schmidt, Simon Nitschky, Simon N. Schmidt, Simon Schmidt

Institution: Lundbeck (Denmark)

Observed institutions: Lundbeck (Denmark), University of California, Irvine, Otsuka (United States), University Medical Center Hamburg-Eppendorf, Lundbeck (United States), Otsuka (United Kingdom), Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)

ORCID: 0000-0002-8754-1875

Observed ORCID: 0000-0002-8754-1875

OpenAlex ID: A5102722765

Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study

2022 · Robert L. Findling, Melissa P. DelBello, et al. · Journal of the American Academy of Child & Adolescent Psychiatry · 39

PDF

Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study

2023 · Michael Cronquist Christensen, Simon Nitschky Schmidt, et al. · Journal of Affective Disorders · 38

Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study

2022 · Michael Cronquist Christensen, Simon Schmidt, et al. · Journal of Psychopharmacology · 32

PDF

Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness

2022 · David S. Baldwin, Oscar Necking, et al. · Journal of Affective Disorders · 25

PDF

Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate

2016 · Steven G. Potkin, Jean-Yves Loze, et al. · The International Journal of Neuropsychopharmacology · 25

PDF

Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study

2017 · Dieter Naber, Ross A. Baker, et al. · Schizophrenia Research · 21

PDF

Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies

2023 · Gregory W. Mattingly, Oscar Necking, et al. · Current Medical Research and Opinion · 20

PDF

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study

2019 · Eduard Vieta, Ioana Florea, et al. · International Clinical Psychopharmacology · 16

Minimal clinically important change in the MADRS anhedonia factor score: A pooled analysis of open-label studies with vortioxetine in patients with major depressive disorder

2024 · Roger S. McIntyre, Oscar Necking, et al. · Journal of Affective Disorders · 15

Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study

2017 · Steven G. Potkin, Jean-Yves Loze, et al. · PLoS ONE · 10

PDF

Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial

2026 · Lotte Kjærsgaard, Jonas Wiedemann, et al. · The Lancet Neurology · 9

The Functioning Assessment Short Test (FAST): Clinically meaningful response threshold in patients with major depressive disorder receiving antidepressant treatment

2024 · Michael Cronquist Christensen, Simon Nitschky Schmidt, et al. · Journal of Affective Disorders · 6

Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study

2024 · Michael Adair, Rohini Bose, et al. · Current Medical Research and Opinion · 4

Vortioxetine in children and adolescents with major depressive disorder: 6-month and 18-month open-label, flexible-dose, long-term extension studies

2024 · Melissa P. DelBello, Robert L. Findling, et al. · European Child & Adolescent Psychiatry · 3

PDF

Functional improvement as a treatment goal in major depressive disorder: a narrative review of the evidence for vortioxetine

2025 · Pratap Chokka, Lene Hammer-Helmich, et al. · Current Medical Research and Opinion · 2

Vortioxetine for Major Depressive Disorder in Children: 12-Week Randomized, Placebo-Controlled Study

2024 · Michael Huss, Robert L. Findling, et al. · JAACAP Open · 2

P.0073 The RECONNECT study: effectiveness of vortioxetine (10–20 mg/day) in patients with major depressive disorder comorbid with generalised anxiety disorder

2021 · M. Christensen, S. Schmidt, et al. · European Neuropsychopharmacology · 1

Vortioxetine in Subgroups of Patients with Major Depressive Disorder and Early-Stage Dementia: Further Results from the MEMORY Study

2026 · Iria Grande, Simon Schmidt, et al. · Neuropsychiatric Disease and Treatment

PDF

The memory study: an effectiveness study of vortioxetine in patients with major depressive disorder and early dementia

2022 · M. Christensen, S. Nitschky Schmidt, et al. · Neuroscience Applied

PDF

Effects of aripiprazole once-monthly and paliperidone palmitate in patients with schizophrenia stratified by disease severity: a post-hoc analysis of QUALIFY

2016 · P. Salzman, S. Nitschky Schmidt, et al. · European Neuropsychopharmacology

Effect sizes of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia: a post-hoc analysis of QUALIFY

2016 · S. Potkin, S. Nitschky Schmidt, et al. · European Neuropsychopharmacology

PM417. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning: a post-hoc analysis of QUALIFY, a head-to-head study in schizophrenia

2016 · Phyllis Salzman, Ross A. Baker, et al. · The International Journal of Neuropsychopharmacology

Works count: 25

Citation count: 268

H-index: 10

I10-index: 10